VEGFA and diabetic retinopathy: Protocol T, an anti-VEGF treatment regimen for DME designed by Diabetic Retinopathy Clinical Research Network, showed that 2 years after the treatment, the change in CST after 3 anti-VEGF injections was a weak determinant of a patient’s subsequent visual acuity outcome [19,20].